GILD Company Profile and Key Details

Q: Who are the executives of GILD?

Ms. Sandra PattersonSenior Vice President, Corporation Controller & Principal Accounting OfficerMs. Deborah H. TelmanExecutive Vice President of Corporation Affairs, Gen. Counsel & Corp. Sec.Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical OfficerMs. Jacquie Ross C.F.A.Vice President of Investor RelationsDr. Michael Quigley Ph.D.Senior Vice President of Research BiologyMs. Diane E. WilfongSenior Vice President, Corporation Controller & Chief Accounting OfficerMr. Daniel P. O'DayChairman & Chief Executive OfficerMr. Andrew D. DickinsonExecutive Vice President & Chief Financial OfficerMs. Johanna MercierChief Commercial OfficerDr. Linda Slanec Higgins Ph.D.Senior Vice President & Head of External InnovationMs. Jyoti K. MehraExecutive Vice President of HR

NASDAQ : GILD

Gilead Sciences

$149.37

3.14+2.15%

At Close 4:00 PM

54.52

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Gilead Sciences, Inc. (GILD) stock surged +2.15%, trading at $149.37 on NASDAQ, up from the previous close of $146.23. The stock opened at $146.50, fluctuating between $145.87 and $150.50 in the recent session.

Stock Snapshot

146.23

Prev. Close

185.32B

Market Cap

145.87

Day Low

18.24

P/E Ratio

8.19

EPS (TTM)

5.95

Cash Flow per Share

146.5

Open

1.24B

Number of Shares

150.5

Day High

99.79%

Free Float in %

18.23

Book Value

9.13M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	146.50	150.50	145.87	149.37	9.12M
Feb 04, 2026	144.14	146.73	143.50	146.23	7.22M
Feb 03, 2026	142.16	145.94	142.03	143.28	6.82M
Feb 02, 2026	141.05	143.80	140.01	142.89	6.87M
Jan 30, 2026	139.08	142.20	138.65	141.95	9.3M
Jan 29, 2026	139.75	140.51	138.23	139.55	7.15M
Jan 28, 2026	140.41	140.87	138.69	139.72	7.09M
Jan 27, 2026	137.54	141.71	137.54	140.97	10.5M
Jan 26, 2026	135.88	138.03	133.69	137.78	9.84M
Jan 23, 2026	131.26	136.30	131.00	135.93	13.18M
Jan 22, 2026	129.13	133.10	129.00	131.14	8.28M
Jan 21, 2026	123.73	129.39	122.68	129.11	7.28M
Jan 20, 2026	123.80	126.24	122.28	124.14	9.08M
Jan 16, 2026	123.80	125.12	122.10	124.91	10.59M
Jan 15, 2026	124.21	124.57	120.94	121.26	6.64M
Jan 14, 2026	121.38	124.16	121.38	124.07	4.66M
Jan 13, 2026	122.59	123.81	120.22	121.76	5.66M
Jan 12, 2026	120.58	124.48	119.63	122.60	7.32M
Jan 09, 2026	120.34	122.76	119.33	121.10	6.58M
Jan 08, 2026	124.08	125.11	119.93	120.67	6.7M

Contact Details

Foster City, CA 94404

United States

https://www.gilead.com 650 574 3000

About Company

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Stock Peers

AMGN

1.6+0.44%

Amgen Inc.$367.80 AZN

-0.29-0.15%

AstraZeneca PLC$187.16 BIIB

-0.09-0.05%

Biogen Inc.$185.36 HZNP

Horizon Therapeutics Public Limited Company$116.30 SNY

-0.59-1.23%

Sanofi$47.49 GRFS

-0.35-3.67%

Grifols, S.A.$9.19 SCLX

-0.89-10.17%

Scilex Holding Company$7.86 MIRA

-0.08-6.61%

MIRA Pharmaceuticals, Inc.$1.13 CTOR

-0.04-3.48%

Citius Oncology, Inc.$1.11 SCLXW

-0.0119-7.83%

Scilex Holding Company$0.14

Company Overview

Gilead Sciences, Inc. (NASDAQ:GILD) closed at $149.37 USD, gaining $3.14 (2.15%) from the previous close of $146.23. The stock is currently trading near its 52-week high $93.37 and $150.50. With a market capitalization of about $185.32 billion, Gilead Sciences, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.39). Key stats such as the average daily volume over the past year has been around 7.22 million shares, in line with its 52-week average. Headquartered in Foster City, CA, Gilead Sciences, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Daniel O'Day, the company employs approximately 17,600 people and listed since January 22, 1992. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Technical Performance

GILD has shown mixed momentum, gaining 1.26% over the past week and 1.08% over the past quarter, though year-to-date performance is up 1.14%. Short-term trend indicators are bearishly aligned (SMA20 12.37%, SMA50 17.64%, SMA200 28.18%). The stock’s 14-day RSI is 79.93 (overbought), while the ATR of 3.65 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 1.8% below its high and over 59.98% above its low. Average 10-day trading volume of 8.01 million shares is slightly above the 3-month average of 7.08 million, indicating heightened recent market interest.

Valuation Metrics

Gilead Sciences, Inc. trades at a P/E ratio of 22.91, slightly below the S&P 500 average, with a price-to-sales ratio of 6.38 and a price-to-book ratio of 8.63 trading at moderately above to book value. The P/FCF stands at 20.24, also above market averages.

Dividend & Fair Value

Gilead Sciences, Inc. last paid a dividend of 3.16 per share, this equals a trailing yield of roughly 3.69%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $218.72. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Gilead Sciences, Inc. generated EPS of $6.46 over the past year. Five-year average earnings growth is -38.13%. Wall Street analysts project EPS growth of 26.89% annually over the next five years. The latest quarter delivered EPS of $2.47. The next quarter is forecast at $1.81. Next year's EPS is expected at $7.59. Analyst sentiment is bullish. Analyst rating data shows there are 16 Strong Buy ratings, 15 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $156.00 to $90.00. The high target offers 4.44% upside. The low target suggests -39.75% downside. The mean target is $131.58. This offers -11.91% upside. Gilead Sciences, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 15.96%. The prior quarter beat by 2.55%. Over the last six quarters, Apple has recorded several small beats. These include 24.84% in August 08, 2024.

Shareholding & Insider Activity

Gilead Sciences, Inc. has 1.24 billion shares outstanding. The public float is 1.24 billion shares, elevated short interest at 1.61% of float. This equals 19.99 million shares. The short ratio is 3.54 days. Institutional investors hold 90.83% of the float. Insiders own 0.1%. GILEAD SCIENCES, INC. holds 14.82 million shares, GILEAD SCIENCES INC has 13.91 million shares and MARTIN JOHN C has 2.88 million shares. Over the past six months, insider transactions show net selling. They sold 198.17 thousand shares across 24 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Gilead Sciences generated $27.12B in revenue, or $21.55 per share. Gross margin was 77.99%, operating margin 34.55%, and net profit margin 20.89%. Returns are healthy, with ROA at 9.12% and ROE at 24.90%.
On valuation metrics, Gilead Sciences trades at a P/E of 22.91, P/S of 6.38 and P/B of 8.63. The current ratio is 1.45 and quick ratio is 1.31. Operationally, the company’s inventory turnover is 3.47 and cash conversion cycle is 121.54 days. Debt-to-equity is 1.16, supported by a cash flow-to-debt ratio of 0.39.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Gilead Sciences posted revenue of $27.12B, down slightly from $27.28B in the prior quarter. Gross profit was $21.15B (margin 77.99%). Operating income was $9.37B (margin 34.5%). Net income was$5.67B (EPS $4.54).
The company ended the quarter with $8.43B in cash and short-term investments, a total debt of $24.99B, and net debt of $18.90B. Total assets were $62.13B, with equity of $22.67B. Financials further reflected stability, with operating cash flow of $8.01B, free cash flow of $7.42B, and capital expenditures of - $585.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that Gilead Sciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.2%, with price expected at $164.61 by February 19, 2026, within a range of $160.97 to $168.36 3-Month Outlook: Projected rise of 15.76%, reaching $172.91 by May 05, 2026, with a range of $170.21 to $175.56. 1-Year Outlook: Projected gain of 8.17%, with price at $161.57 by February 05, 2027, within a range of $156.74 to $165.45.

Key Takeaways

Gilead Sciences, Inc. (NASDAQ:GILD) shares are flat 1.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Gilead Sciences, Inc. trading at a premium to the broader market with a P/E of 22.91. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $100.78, suggesting -32.53% downside. Our AI forecast model points to short-term strength (10.2% over two weeks), a medium-term rise (15.76% over three months), and a longer-term gain (8.17% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Gilead Sciences, Inc. (GILD) stock price?

Gilead Sciences, Inc. (NASDAQ: GILD) stock price is $149.37 in the last trading session. During the trading session, GILD stock reached the peak price of $150.50 while $145.87 was the lowest point it dropped to. The percentage change in GILD stock occurred in the recent session was 2.15% while the dollar amount for the price change in GILD stock was $3.14.

GILD's industry and sector of operation?

The NASDAQ listed GILD is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Gilead Sciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GILD?

Ms. Sandra Patterson
Senior Vice President, Corporation Controller & Principal Accounting Officer
Ms. Deborah H. Telman
Executive Vice President of Corporation Affairs, Gen. Counsel & Corp. Sec.
Dr. Merdad V. Parsey M.D., Ph.D.
Chief Medical Officer
Ms. Jacquie Ross C.F.A.
Vice President of Investor Relations
Dr. Michael Quigley Ph.D.
Senior Vice President of Research Biology
Ms. Diane E. Wilfong
Senior Vice President, Corporation Controller & Chief Accounting Officer
Mr. Daniel P. O'Day
Chairman & Chief Executive Officer
Mr. Andrew D. Dickinson
Executive Vice President & Chief Financial Officer
Ms. Johanna Mercier
Chief Commercial Officer
Dr. Linda Slanec Higgins Ph.D.
Senior Vice President & Head of External Innovation
Ms. Jyoti K. Mehra
Executive Vice President of HR

How GILD did perform over past 52-week?

GILD's closing price is 59.98% higher than its 52-week low of $93.37 where as its distance from 52-week high of $150.50 is -0.75%.

How many employees does GILD have?

Number of GILD employees currently stands at 17,600.

Link for GILD official website?

Official Website of GILD is: https://www.gilead.com

How do I contact GILD?

GILD could be contacted at phone 650 574 3000 and can also be accessed through its website. GILD operates from 333 Lakeside Drive, Foster City, CA 94404, United States.

How many shares of GILD are traded daily?

GILD stock volume for the day was 9.13M shares. The average number of GILD shares traded daily for last 3 months was 7.22M.

What is the market cap of GILD currently?

The market value of GILD currently stands at $185.32B with its latest stock price at $149.37 and 1.24B of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	17600
Beta	0.35
Sales or Revenue	$27.12B
5Y Sales Change%	0.275%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

GILD Company Profile and Key Details

Gilead Sciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook